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ABSTRACT
The collagenase subfamily of matrix metallo-
proteinases (MMP) have important roles in the re-
modelling of collagenous matrices. The proteinase-
activated receptor (PAR) family have a uniquemech-
anism of activation requiring proteolysis of an ex-
tracellular domain forming a neo-N terminus which
acts as a tethered ligand, a process that has been as-
sociated with the development of arthritis. Canon-
ical PAR2 activation typically occurs via a serine
proteinase at Arg36-Ser37, but other proteinases can
cleave PARs downstream of the tethered ligand and
“disarm” the receptor. To identify additional cleav-
age sites within PAR2, we synthesised a 42-amino
acid peptide corresponding to the extracellular re-
gion. We observed that all three soluble MMP
collagenases - MMP-1, MMP-8, and MMP-13 -
cleave PAR2 and discovered a novel cleavage site
(Ser37-Leu38). Metalloproteinases from resorbing
bovine nasal cartilage and recombinant human colla-
genases could cleave a quenched fluorescent peptide
mimicking the canonical PAR2 activation region,
and kinetic constants were determined. In PAR2-
overexpressing SW1353 chondrocytes, we demon-
strated that the activator peptide SLIGKV-NH2 in-
duces rapid calcium flux, inflammatory gene expres-
sion (including MMP1 and MMP13), and the phos-
phorylation of extracellular signal–regulated kinase
(ERK) and p38 kinase. The corresponding MMP
cleavage–derived peptide (LIGKVD-NH2) exhib-
ited no canonical activation, however we observed
phosphorylation of ERK, providing evidence of bi-
ased agonism. Importantly, we demonstrated that
pre-incubation with active MMP-1 reduced down-
stream PAR2 activation by a canonical activator,
matriptase, but not SLIGKV-NH2. These results
support a role for collagenases as proteinases ca-
pable of disarming PAR2, revealing a mechanism
which suppresses PAR2-mediated inflammatory re-
sponses.
Proteinases are enzymes that effect proteol-
ysis of intact proteins via the hydrolysis of peptide
bonds(1) and are essential in amyriad of situations in
both health and disease, such as extracellular matrix
(ECM) remodelling during development or patho-
logical destruction. In humans, almost two thirds of
the proteinases that comprise the degradome(2) exert
their activities within the extracellular space making
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them prime candidates in events that entail remod-
elling and/or degradation of the ECM. These can be
sub-divided intometallo- and serine proteinases, and
in this context these proteinases have until recently
been viewed as mediating the proteolytic degrada-
tion of ECM components as occurs for example in
tumour invasion or arthritis. However, it is now
clear that proteinases also perform precise and spe-
cific functions in both homeostasis and disease. The
cleavage of triple helical collagens such as type II
collagen (the major structural component present in
cartilage) by the soluble collagenase subset ofmatrix
metalloproteinases (MMP-1, MMP-8 and MMP-13)
represents an example of highly specific proteolysis
whereby only a single peptide bond is cleavable un-
der normal physiological conditions(3). This initial
cleavage then leads to collagen denaturation, con-
comitant with increased susceptibility to other less
specific proteinases and disassembly of the colla-
gen network which is a requirement as cartilage is
remodelled into bone during development, but also
occurs during cartilage breakdown in degenerative
scenarios such as rheumatoid arthritis (RA) and os-
teoarthritis (OA).
Proteinase activated receptors (PARs) rep-
resent one mechanism by which proteinases can del-
icately regulate cellular responses and are likely to
be involved in many disease processes. The impor-
tance of PAR2 in the pathogenesis of both inflam-
matory arthritis and OA has recently emerged, and
PAR2 deficiency provides protection in experimen-
tal arthritis models(4–9). We have demonstrated
that an activator of PAR2, matriptase, induces carti-
lage destruction in a PAR2- and metalloproteinase-
dependent manner(10, 11) and that a related serine
proteinase, hepsin, can also activate PAR2 albeit
in a markedly less efficient manner(12). Indeed,
in complex disease environments (such as arthritis)
multiple proteinases could be present to act on PAR2
making our understanding of how PAR2 is activated
and regulated important (reviewed in (13)).
PAR2 exhibits receptor plasticity with bi-
ased signalling: different proteinases eliciting dif-
ferent downstream responses following cleavage of
the extracellular domain which may be of particular
importance in modulating inflammatory responses
(see (14, 15)). Here, we investigated the effect of
collagenolytic MMPs, known to be expressed dur-
ing ECM remodelling events(16), on PAR2. We
identified novel cleavages by MMP-1, -8 and -13
and a primary cleavage site common to all was iden-
tified. Collagenase cleavage resulted in antagonism
of PAR2 activation, suggesting an important nega-
tive feedback mechanism whereby canonical PAR2
activation inducesMMP expression whilstMMP ac-
tivity can subsequently antagonise PAR2.
RESULTS
MMP Collagenases cleave the PAR2 ex-
tracellular domain—To determine which col-
lagenolyticMMPs can cleave the extracellular PAR2
sequence, we synthesised a 42-amino acid peptide,
corresponding to the N-terminal extracellular re-
gion of PAR2 (PAR231−72 peptide) where previ-
ous PAR2 cleavage sites have been identified(17–
19) (Fig. 1A). After confirming the peptide was
cleaved by known PAR2-cleaving proteinases (Fig.
1B) the peptidewas incubatedwithAPMA-activated
MMP-1, MMP-8 and MMP-13. Silver-stained SDS-
PAGE gels of the digested products demonstrated
that all three collagenases were capable of cleav-
ing this sequence in a dose-dependent manner (Fig.
1C). Cleavage was subsequently confirmed by re-
verse phase HPLC (Fig. 2A-C), and peaks were
collected and subjected to electrospray MS. Exact
mass identifications revealed cleavage sites for each
collagenase (Fig. 2D), but interestingly, time course
experiments identified a primary cleavage common
to all, following Ser37 (Fig. 3). This novel site is
adjacent to the canonical cleavage site described for
trypsin-like serine proteinases, Arg36.
Collagenases cleave a PAR2 synthetic pep-
tide substrate—To further explore and determine
kinetic constants for collagenase cleavage of PAR2,
a quenched fluorescent peptide mimic of PAR2
was employed (2-Abz-SKGRSLIG-Y(NO2)). To
demonstrate cleavage by native MMPs, the peptide
was incubated with conditioned medium from 14-
day IL-1+OSM-stimulated bovine nasal cartilage,
a well-established model of proteinase-driven carti-
lage breakdown(10, 20, 21). Cleavagewas observed;
however, this was completely abolished by the ad-
dition of the MMP inhibitor GM6001, but not by
serine or cysteine proteinase inhibition (Fig. 4A).
Subsequently, recombinant APMA-activated MMP-
1, -8 and -13 were shown to cleave the peptide,
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with the effect dependent on active site accessibility
(Fig. 4B). Velocity was calculated from progress
curves at variable concentrations of substrate and
the resultant plots are consistent with each colla-
genase exhibiting Michaelis-Menten kinetics (Fig.
4C). APMA-activated MMP-1, MMP-8 and MMP-
13 exhibited similar KM values for this substrate
36-53 µM, which are similar to that of matriptase
(46.6 µM). MMP-13 exhibited the highest turnover
number (kcat ) of all three collagenases, and therefore
the highest catalytic efficiency (kcat /KM ) although
this was markedly lower than that of matriptase (Fig.
4D).
Canonical PAR2 activation induces col-
lagenolytic MMP expression—To generate a model
of chondrocytes expressing higher levels of PAR2 (as
is the case in OA(22, 23)), we overexpressed PAR2
using a lentivirus transduction system. SW1353
cells transduced with a PAR2-expressing lentivirus
(hereafter, SW1353-PAR2; dependency of PAR2 ex-
pression validated in Fig. S1) were stimulated with
the PAR2 activator peptide, SLIGKV-NH2, which
resulted in calcium mobilisation (Fig. 5A). Further-
more, stimulation for varying durations resulted in
ATF3, MMP1 and MMP13 gene expression (Fig.
5B,C). ATF3 is a transcription factor we recently
identified as regulating MMP13 expression follow-
ing cytokine stimulation(24). Secreted MMP-1 and
MMP-13 were subsequently detected in the culture
medium 48 hours post-stimulation (Fig. 5D).
The N-terminus generated by collagenase
cleavage does not activate canonical PAR2 sig-
nalling—Due to the proximity of the primary col-
lagenase cleavage site to the canonical PAR2 acti-
vation sequence, the effect of the resultant neo-N-
terminus on PAR2 activation was investigated by
synthesising a peptide corresponding to the puta-
tive tethered ligand: LIGKVD-NH2 (see Fig. 2D).
SW1353-PAR2 cells stimulated with LIGKVD-
NH2, or the control reverse peptide (DVKGIL-NH2)
exhibited no calcium mobilisation (Fig. 6A) nor the
expression of ATF3 or MMP1 (Fig. 6B).
The collagenase derived PAR2 peptide
LIGKVD-NH2 induces biased Mitogen-activated
protein kinase (MAPK) phosphorylation—MAPK
phosphorylation is a well characterised downstream
output of canonical PAR2 activation(25–27). In-
deed, herein we confirm that SLIGKV-NH2 (Fig.
6C) induces phosphorylation of ERK and p38 at
early timepoints. Intriguingly, LIGKVD-NH2 in-
duced ERK but not p38 phosphorylation (Fig. 6D),
whilst the control reverse peptide did not markedly
induce either MAPK (Fig. 6E).
Collagenase cleavage antagonises PAR2—
To determine the effect of collagenase cleavage on
the potential for PAR2 to be subsequently activated
by canonical PAR2 activators, we performed pre-
incubation experiments. When recombinant ac-
tive MMP-1 was pre-incubated with SW1353-PAR2
cells, matriptase-induced PAR2 activation was abro-
gated, but importantly, activation by SLIGKV-NH2
was not (Fig. 7A). There was no evidence of ATF3
induction by MMP1 on either SW1353 control cells
or SW1353-PAR2 cells (Fig. 7B). SW1353-PAR2
cells pre-incubated with LIGKVD-NH2 markedly
reduced the capacity for canonical activation by
the SLIGKV-NH2 (Fig. 7C), whereas cells pre-
incubated with the control reverse peptide did not
(Fig. 7D).
DISCUSSION
It is becoming increasingly clear that pro-
teolysis not only mediates catabolic events but can
also act to precisely regulate cellular processes. One
such example, the PARs, represent a way in which
controlled cleavage of a substrate by different pro-
teinases leads to different downstream events and
outcomes. In this study, we outline such regula-
tion of PAR2 by a family of proteinases that, to
our knowledge, have not been investigated before in
this context. We demonstrated that the collagenases
MMP-1, -8 and -13 can cleave the PAR2 extracel-
lular region, with MMP-1 yielding a single product
resulting from cleavage at Ser37-Leu38 with an ad-
ditional cleavage at Val68-Leu69 observed following
MMP-8 and -13 incubations. These cleavage sites
are in agreement with the described substrate speci-
ficities of the collagenases which show a preference
for a hydrophobic residue in the P1’ position, a basic
or hydrophobic amino acid in the P2’ position, and a
small amino acid in the P3’ position(28–30). Thus,
the Ser37-Leu38 site fits this preference with leucine,
isoleucine and glycine in P1’ - P3’, respectively;
whilst the Val68-Leu69 site fits at the P1’ and P3’
positions (leucine and glycine, respectively). Taken
together with time course experiments, it is likely
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that Ser37-Leu38 is the primary collagenase cleav-
age site on PAR2. It remains possible, however, that
both cleavages could hold functional relevance. For
example, following canonical PAR2 activation by
mast cell tryptase, signalling has been shown to be
attenuated by a secondary downstream cleavage(31).
The kinetic profiles of PAR2 cleavage by
the collagenases were explored and compared with
matriptase, a potent activator of PAR2(12). Un-
surprisingly, all three collagenases were less effi-
cient at cleaving the substrate compared to matrip-
tase (which exhibited similar kinetics to previously
published findings(32, 33)), primarily as a result of
lower kcat values, with broadly similar KM values.
When considering the enzyme kinetics of the colla-
genases, it is important to note that APMA-activated
proMMPs were utilised, which are not considered
to be fully active with 10-25% of maximal activ-
ity typically observed when compared to MMP-3
activated proMMP(34); thus, the collagenase kinet-
ics for PAR2 may be underrepresented compared to
in vivo cleavage. Furthermore, the abundance of
MMPs is an important consideration, since tissues
undergoing active remodelling, such as during car-
tilage destruction in arthritis, have high expression
levels of MMPs(35–37). Taken together, these data
suggest that the collagenases andmatriptase can bind
PAR2with broadly similar affinities, but the collage-
nases are less efficient at turning over the substrate.
Data presented within the present study
demonstrate that the addition of active MMP-1 to
PAR2-expressing cells, followed by the activation of
PAR2 by matriptase exhibit an attenuated level of
activation; importantly a result not observed follow-
ing SLIGKV-NH2 activation. This observation can
be interpreted as cleavage of PAR2 by MMP-1 in a
classical disarming mechanism similar to cathepsin
G or proteinase 3 disarming of PAR2(17, 38). This
would entail the cleavage of PAR2 at Ser37-Leu38
thus removing the canonical activation site to leave
a disarmed receptor on the surface (as evidenced by
full SLIGKV-NH2 activation).
Cleavage of cell surface receptors by col-
lagenases has previously been described, with both
MMP-1(39) and -13(40) having been shown to be
able to activate the PAR1 receptor by cleavage at two
amino acids upstream, or a single amino acid down-
stream, of the canonical site, respectively. Further-
more, low levels of trypsin-activated MMP-1 have
been previously described to upregulate monocyte
chemoattractant protein-1 (MCP-1) in A549 cells
(which endogenously express PAR2) however no
mechanism nor cleavage site were described(41).
Both PAR2(23) and matriptase(10) are ex-
pressed significantly higher inOAchondrocytes than
in normal chondrocytes, whichmay contribute to the
elevated levels of MMP-1 and MMP-13 expression
observed in the disease(22). We have previously
shown matriptase to induce MMP expression in ex-
plant OA cartilage(10), and herein we show PAR2
activation in chondrocytes leads to the expression
and secretion of both these collagenases. To our
knowledge, the expression of MMP-1 and MMP-13
in chondrocytes following PAR2 activation is a novel
observation, although the addition of SLIGKV-NH2
to OA cartilage has previously been shown to in-
crease MMP-1 and MMP-13 immunostaining(22).
Aside from the collagenases, other MMPs including
MMP2(42), MMP3(43) and MMP9(44) have been
shown to be induced by PAR2 activation in various
cell types.
Biased agonism following activator peptide
stimulation of PAR2 has previously been explored.
The peptide SLAAAA-NH2 has been shown to in-
duce ERK1/2 phosphorylation in the absence of cal-
cium mobilisation(45) as observed with LIGKVD-
NH2 in the present study. In rat PAR2, ALIGRL-
NH2 peptide (based on the rat canonical activation
sequence, SLIGRL) has been shown to result in de-
tectable canonical PAR2 activation (as measured by
calcium mobilisation), with no detectable activa-
tion when substituting the P2’ leucine for alanine
(SAIGRL-NH2) – identifying a key role for the P2’
leucine in canonical activation(46). In the present
study, this P2’ leucine becomes the P1’ leucine
and no calcium mobilisation was detected. Fur-
thermore, the presence of a basic amino acid in
P5’ has been postulated as a requirement for cal-
cium mobilisation(47), which is lost in LIGKVD
compared to SLIGKV (underlined). Data presented
within the present study suggest competitive bind-
ing in the extracellular region of PAR2 between the
two similar sequences, SLIGKV and LIGKVD, de-
spite their differing downstream effects. The func-
tional consequences of ERK1/2 phosphorylation in-
duced by the collagenase-derived peptide requires
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further investigation, although this does not involve
the activation of canonical PAR2 signalling path-
ways or downstream induced genes such as ATF3
and MMP1.
The data presented herein support a mecha-
nism by which collagenolytic MMPs, the expression
of which are induced by canonical PAR2 activation,
negatively regulate PAR2 by abrogating its canonical
activation (Fig. 8).
EXPERIMENTAL PROCEDURES
Materials—Unless stated otherwise, all
chemicals were of the highest purity available and
obtained from Sigma Aldrich (Gillingham, UK). All
proteins were recombinant human, except cathep-
sin G and neutrophil elastase which were purified
from human sputum (Elastin Products, Owensville,
USA). Matriptase(11), hepsin(12) proMMP-1, and
proMMP-13(48) were all prepared as previously
described. proMMP-8 was obtained from R&D
Biosystems (Abingdon, UK). Tissue inhibitor of
metalloproteinases-1 (TIMP-1) was a kind gift from
Prof Hideaki Nagase (Oxford University, UK). The
SLIGKV-NH2 peptide was purchased from Abcam
(Cambridge, UK), (Abz-Ser-Lys-Gly-Arg-Ser-Leu-
Ile-Gly-Tyr(NO2)) substrate was from GL Biochem
(Shanghai, China) whilst peptides LIGKVD-NH2
and DVKGIL-NH2 were synthesised by Peptide
Synthetics (Fareham, UK). MMP inhibitor GM6001
was from Merck Millipore (Watford, UK).
Cell culture—SW1353 chondrosarcoma
cells were purchased from American Type Culture
Collection (cat. no. HTB-94; Rockville, MD).
Cells were cultured at 37°C inDMEM/F-12medium
supplemented with 2mM L-glutamine, 100 IUml−1
penicillin and 100 µgml−1 streptomycin, and 10%
foetal bovine serum (all from Thermo Fisher, Pais-
ley, UK). Cells were starved in serum-free medium
for at least 6 hours prior to stimulation.
Lentivirus generation and transduction—
The lentiviral expression plasmid pSIEW-hPAR2
was constructed using a BamHI-tagged hu-
man PAR2 PCR product generated from the
human PAR2 VersaClone cDNA (RDC0166,
R&D Biosystems) with primers: For, 5’-AAAA
GGATCCGCCACCATGCGGAGCCCCAGC-
3’ and Rev, 5’-GCGCGGCCGCGGATCCTC
AATAGGAGGTCTTAACAGTGGTTGAAC-3’
prior to routine sub-cloning into BamHI-digested
pHR-SINcPPT-SIEW (a generous gift from Prof.
Olaf Heidenreich, Newcastle University, UK).
Lentiviruses were generated in HEK293T
cells following transfection with pSIEW-hPAR2,
pCMV∆8.91 and pVSV-G (both supplied by Prof.
Heidenreich, Newcastle University, UK) according
to standard protocols, and concentrated using the
Lenti-X kit (ClonTech, Mountain View, USA).
SW1353 cells at 50% confluency were
transduced for 48 hours with lentivirus in serum-
containing DMEM-F12 supplemented as above with
the addition of 4 µgml−1 polybrene at a 1:200 con-
centrated virus:medium ratio. Cells were assessed
for successful transduction by examining GFP ex-
pression using inverted fluorescence microscopy,
and then serum-starved for a minimum of 6 hours
prior to use.
Peptide Digestion and Visualisation—
A 42 amino acid peptide corresponding to
amino acids 31–72 of human PAR2 (H2N-
RSSKGRSLIGKVDGTSHVTGKGVTVETVFSV-
DEFSASVLTGK-COOH) was synthesised (see
Supporting Information), (PAR231−72 peptide). The
peptide was incubated at a final concentration of
10 µM with various proteinases at 37°C for vary-
ing durations (see Supporting Information for full
details of incubation buffers).
For visualisation, samples were resolved on
20% polyacrylamide Tris-Tricine gels(49), which
were subsequently fixed for 1 hour in 12%
trichloroacetic acid/ 30% methanol followed by sil-
ver staining using a Plus One silver staining kit
(GE healthcare, Little Chalfont, UK) according to
the manufacturer’s instructions. Mass Spectrometry
(MS) – Analytical reverse phase HPLC (RP-HPLC)
and infusion electrospray MS and were performed
as previously described(50)with somemodifications
(see Supporting Information).
Enzyme Kinetics— ProMMPs were acti-
vated with 1mM APMA and then active-site
titrated with TIMP-1(51) using Mca-Lys-Pro-Leu-
Gly-Leu-Dpa-Ala-Arg-NH2 (FS-6; Sigma-Aldrich)
as substrate. Matriptase was titrated using 4-
methylumbelliferyl 4-uanidinobenzoate hydrochlo-
ride as described(11). Michaelis-Menten ki-
netic analyses were performed by incubating a
fixed concentration of active-site titrated proteinase
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(400.4 nM MMP-1, 172.8 nM MMP-8, 9.01 nM
MMP-13 and 1 nM matriptase) with 0-100 µM 2-
Abz-SKGRSLIG-Y(NO2) substrate. Assays were
performed in a FLUOstar OPTIMA fluorimeter
(BMG Labtech, Aylesbury, UK) at 37°C, λex
320 nm, λem 420 nm, ensuring linearity of sub-
strate hydrolysis prior to further quantification. Sub-
strate hydrolysis was quantified using a standard
curve representing total substrate hydrolysis at each
concentration. Non-linear regression analysis was
performed to generate kinetic constants KM and
Vmax (GraphPad Prism Software), and kcat calcu-
lated. Conditioned medium from an IL-1+OSM-
stimulated bovine nasal cartilage explant cultures
was generated as previously(12).
Calcium mobilisation assay— Following
serum-starvation of SW1353 cells transduced in
black-walled clear bottom 96-well plates, cells were
washed with 200 µL Hank’s Balanced Salt Solu-
tion supplemented with 20mM HEPES, pH 7 and
2mM CaCl2 (HHBS/Ca2+). To each well, 50 µL
of a 5 µM stock solution of the calcium indicator
Rhod-4 AM (Santa Cruz, Heidelberg, Germany) in
HHBS/Ca2+ supplemented with 2.5mM probenecid
(Santa Cruz) and 0.02% pluronic F-127 (Thermo
Fisher) was added and incubated at room temper-
ature in the dark for 45 minutes. Cells were then
washed with HHBS/Ca2+ before incubating at room
temperature for 20 minutes in HHBS/Ca2+ to allow
for dye de-esterification.
Assays were performed in a FLUOstar OP-
TIMA fluorimeter (BMG Labtech) at 37°C during
which its injection pumps were each primed with
2mL of HHBS/Ca2+, before priming with 1mL of
test solutions. The test solution in pump A was
always at 2x final concentration, whereas the test
solution in pump B was at 3x final concentration.
To perform the assay, each well was replaced with
30 µL HHBS/Ca2+, and placed in the fluorimeter
programmed to read in single-well mode (readings
taken every second at λex 520 nm and λem 590 nm).
For each assay, a 10 second baseline was established
before 30 µL injection from pump A, 90 seconds
incubation followed by 30 µL injection from pump
B.
Active Matrix Metalloproteinase-1 Produc-
tion—Purified active MMP-1 was produced for
cell culture work to avoid addition of APMA
on cells. Recombinant human proMMP-1 was
expressed in Escherichia coli and refolded from
chaotrope-solubilised inclusion bodies as described
previously(52). The refolded pro-enzyme was pu-
rified using an automated two-step procedure on an
ÄKTAxpress system (GE Healthcare): 1) immo-
bilised metal ion affinity chromatography (IMAC)
using a Ni2+-charged 5mL HiTrap IMAC FF col-
umnwith 50mMTris pH 7.4, 150mMNaCl, 10mM
CaCl2 (TNC) as binding buffer, and an elution buffer
of TNC supplemented with 0.5M imidazole; 2)
size-exclusion chromatography (SEC) performed on
a HiLoad 26/60 Superdex 75 prep grade column
with TNC as running buffer. Following incubation
with APMA and MMP-3(53), the activated MMP-
1 was re-purified by tandem IMAC-SEC as above.
Aliquots of 5 µM MMP-1 were lyophilised from
TNC buffer supplemented with 1% (w/v) BSA and
stored at -80°C until required.
Assessment of PAR2 receptor Antago-
nism—Lyophilised active MMP-1 was resuspended
to 1 µM in DMEM-F12 medium supplemented with
10mM CaCl2 and subsequently added to cells for
the required time. Matriptase or SLIGKV-NH2 was
added at twice the final concentration and cells in-
cubated for the required time at 37°C prior to RNA
extraction (see below).
Gene expression analyses—RNA was ex-
tracted from cells in a 96-well format using Cells-to-
cDNA lysis buffer (Thermo Fisher) according to the
manufacturer’s instructions, prior to cDNA synthe-
sis by MMLV reverse transcriptase (Thermo Fisher)
according to manufacturer instructions. Real-time
(q)PCR was performed using TaqMan Fast Ad-
vanced Master Mix with the following cycling con-
ditions (QuantStudio 3, Thermo Fisher): 2 minutes
at 50°C, 20 seconds at 95°C followed by 40 cycles
of 1 second at 95°C, 20 seconds at 60°C. Primer
and probe sequences for MMP1, MMP13(54),
and ATF3(24) as previously described. GAPDH
expression was measured using: Forward 5’-
GTGAACCATGAGAAGTATGACAAC-3’; reverse
5’-CATGAGTCCTTCCACGATACC-3’; and probe
Fam-CCTCAAGATCATCAGCAATGCCTCCTG-
Tamra.
SDS-PAGE and Immunoblotting—Whole
cell lysates were generated using RIPA buffer
(150mM sodium chloride, 1.0% Triton X-100,
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0.5% sodium deoxycholate, 0.1% SDS, 50mM
Tris, pH 8.0, 10mM sodium fluoride and 1mM
sodium orthovanadate, supplemented with a cOm-
plete Mini Protease Inhibitor Cocktail tablet). Sam-
ples were prepared and SDS-PAGE performed as
previously(12). Proteins were transferred to PVDF
membrane using a Trans-Blot SDSemi-DryTransfer
Cell (BioRad, Watford, UK) according to the man-
ufacturer’s instructions, and incubated with primary
antibody overnight at 4°C. Antibodies used were:
phospho-p38 (#4511), phospho-ERK1/2 (#9101),
ERK1/2 (#9102) from Cell Signalling Technology
(Danvers, USA) and p38 (SC-535) from Santa Cruz.
Enzyme-linked immunosorbent assay
(ELISA)—Total MMP-1 was measured as previ-
ously described(55), whereas total MMP-13 was
measured using a Human Total MMP-13 DuoSet
ELISA kit (R&D Biosystems) according to the
manufacturer’s instructions.
Statistical analyses—Statistical differences
between sample groups were assessed using the Stu-
dent’s 2-tailed unpaired t-test, where ***p<0.001,
**p<0.01, *p<0.05. For clarity, only selected com-
parisons are presented in some figures.
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Figure 1: The collagenases are able to cleave the PAR2 extracellular domain. A 42 amino acid peptide
corresponding to Arg31-Lys72 of the extracellular domain of PAR2 (denoted in red) was produced. Various
known cleavage sites are highlighted: the canonical activation site (trypsin, matriptase etc., with the tethered
ligand/activator peptide sequence underlined); CS = cathepsin S; PR3 = proteinase 3; CG = cathepsin G; NE
= neutrophil elastase (A). The PAR231−72 peptide (10 µM) was incubated with 10 nM of hepsin or elastase, or
1 nM cathepsin G, or 0.1 nM matriptase for the indicated durations before resolving on 20% polyacrylamide
gels utilising a Tris-Tricine buffer system and silver staining. S = substrate, P = product. Presented gels are
representative of at least two independent experiments (B). The PAR231−72 peptide (10 µM) was incubated
with increasing concentrations of APMA-activated recombinant proMMP-1, -8 and -13 for 24 hours before
resolving on 20% polyacrylamide gels utilising a Tris-Tricine buffer system and silver staining. S = substrate,
P = product. The presented gels are representative of three independent experiments (C).
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Figure 2: The MMP collagenases cleave PAR2 at a novel site. The PAR231−72 peptide (10 µM) was
incubated with APMA-activated MMP-1 (400 nM; A), MMP-8 (20 nM; B) or MMP-13 (200 nM; C) for
24 hours and reversed-phase HPLC performed. HPLC chromatograms are representative of at least two
independent experiments, and are presented as separate graphs for claritywith the same control chromatogram
presented in each panel. Peaks identified by HPLC were collected and subjected to further analysis by
electrospray MS, which identified MMP-derived cleavage sites at Ser37-Leu38 and Val68-Leu69, to reveal a
putative neo-epitope tethered ligand (underlined in D). The coloured arrows (A-C) and lines (D) indicate
the following: red = parent peptide; green = Ser37-Leu38 cleavage; amber = Val68-Leu69 cleavage; blue =
Ser37-Leu38 and Val68-Leu69 cleavage. Observed masses are presented in Supporting Table S1.
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Figure 3: Time-course of PAR231−72 cleavage byMMP-13. PAR231−72 peptide (10 µM)was incubatedwith
APMA-activated proMMP-13 (200 nM) over a 24 hour timecourse as indicated (A-D), and reversed-phase
HPLC performed. Arrows indicate identity of observed peaks: red = parent peptide; green = Ser37-Leu38;
blue = Ser37-Leu38 + Val68-Leu69. Presented HPLC chromatograms are representative of three independent
experiments.
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Figure 4: The collagenases cleave PAR2 with varying efficiencies. 2-Abz-SKGRSLIG-Y(NO2) peptide
(10 µM) was incubated with day 14 conditioned media from IL-1+OSM-stimulated bovine nasal cartilage
explant cultures in the presence or absence of 100 µM GM6001, 10 µM E64 or 2mM DFP. Data (mean ±
S.D.) are normalised to the no inhibitor control sample and are representative of at least two independent ex-
periments with conditioned media from different cartilages (A). 2-Abz-SKGRSLIG-Y(NO2) peptide (50 µM)
was incubated with APMA-activated recombinant proMMP-1 (50 nM), -8 (10 nM) or -13 (20 nM) in the
presence or absence of 50 µM GM6001 or DMSO-only control, and data normalised to the inhibitor/DMSO
negative sample (mean ± S.D.), combining means (each with n=2 technical replicates) from four independent
experiments (B).Michaelis-Menten curves (mean± S.D.; presented graphs show combinedmeans (eachwith
n=2 technical replicates) of three independent experiments) were generated using TIMP-1-titrated APMA-
activated recombinant proMMP-1, -8 and -13 (C). The hydrolysis of substrate was quantified (nM.s−1) using
a standard curve determined by total substrate hydrolysis, and non-linear regression analysis performed to
generate kinetic constants KM and Vmax . kcat was subsequently calculated from Vmax and active enzyme
concentration. Tabulated kinetic constants (mean ± S.D.) are from three independent experiments. Ma-
triptase kinetic parameters included for comparison (D). Selected statistical comparisons performed using
student’s two-tailed unpaired t tests, where ***, p<0.001.
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Figure 5: Activation of PAR2 by the canonical activator peptide SLIGKV-NH2 results in MMP1,
MMP13 and ATF3 expression. SW1353-PAR2 cells (blue lines) or empty vector control cells (red lines)
loaded with Rhod-4-AM fluorescent calcium probe were subjected to titrations of 0-10 µM SLIGKVD-NH2
(injected at arrow S) followed by 5 µM ionomycin (injected at arrow Io) and calcium mobilisation measured.
Data are presented relative to basal fluorescence (at 0 seconds) and are representative of two independent
experiments (each with n=3 technical replicates) (A). SW1353-PAR2 cells were stimulated with 100 µM
SLIGKV-NH2 for the indicated times and RT-qPCR performed for ATF3 (B),MMP1 andMMP13 (C). Data
are expressed relative toGAPDH and presented as fold-change comparedwith basal expression (mean± S.D.,
n=4), representative of two independent experiments. SW1353-PAR2 or empty vector control cells were
stimulated with 100 µM SLIGKV-NH2 for 48 hours, and the conditioned medium used to perform MMP-1
and MMP-13 ELISAs. Data presented as mean ± S.D., representative of three independent experiments
(each with n=6 technical replicates) (D). Selected statistical comparisons performed using student’s two-
tailed unpaired t tests against basal (unstimulated), where ***, p <0.001; **, p <0.01; *, p <0.05 for MMP1
and ATF3; and ###, p <0.001; ##, p <0.01; #, p <0.05 for MMP13.
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Figure 6: LIGKVD-NH2 is not a canonical PAR2 activator. SW1353-PAR2 cells (blue lines) or empty
vector control cells (red lines) loaded with Rhod-4-AM fluorescent calcium probe were subjected to titrations
of 0-100 µMLIGKVD-NH2 (left panel) or DVKGIL-NH2 (right panel), injected at arrowL or D, respectively,
followed by 5 µM ionomycin (injected at arrow Io) and calcium mobilisation measured. Data are presented
relative to basal fluorescence (at 0 seconds) and are representative of two independent experiments (each
with n=3 technical replicates) (A). SW1353-PAR2 cells were stimulated with 100 µM SLIGKV-NH2, 100 µM
LIGKVD-NH2, 100 µM DVKGIL-NH2 or 50 nM matriptase for 90 minutes (left panel) or 24 hours (right
panel) and RT-qPCR performed for ATF3 or MMP1. Data are expressed relative to GAPDH and presented
as fold-change compared with basal expression (mean ± S.D., n=6), representative of three independent
experiments (B). SW1353-PAR2 or empty vector control cells were stimulated with 100 µM SLIGKV-NH2
(C), 100 µM LIGKVD-NH2 (D) or 100 µM DVKGIL-NH2 (E) for the indicated times and then cell lysates
immunoblotted for phospho-ERK1/2, ERK1/2, phospho-p38 or p38. Combined densitometric scans of three
independent experiments (mean ± S.D.) are presented. Statistical comparisons performed using student’s
two-tailed unpaired t tests comparing stimulated cells with basal, where ***, p <0.001; **, p <0.01; *, p
<0.05.
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Figure 7: MMP1 is antagonistic to canonical PAR2 activation. SW1353-PAR2 cells were pre-treated
with either 1000 nM active MMP-1 or serum-free medium (SFM) for 120 minutes prior to the addition of
10 nM matriptase or 100 µM SLIGKV-NH2 for an additional 60 minutes and RT-qPCR performed for ATF3
(A). SW1353-PAR2 or empty vector control cells were stimulated with either 1000 nM active MMP-1 or
100 µM SLIGKV-NH2 for 60 minutes and RT-qPCR performed for ATF3 (B). SW1353-PAR2 cells were pre-
treated with 100 µM LIGKVD-NH2 or SFM for 120 minutes prior to the addition of 100 µM SLIGKV-NH2
for an additional 60 minutes and RT-qPCR performed for ATF3 (C). SW1353-PAR2 cells were pre-treated
with 100 µM DVKGIL-NH2 or SFM for 120 minutes prior to the addition of 100 µM SLIGKV-NH2 for an
additional 60 minutes and RT-qPCR performed for ATF3 (D). Data are expressed relative to GAPDH and
presented as fold-change compared with basal expression (mean ± S.D., n=6), representative of at least three
independent experiments. Selected statistical comparisons performed using student’s two-tailed unpaired t
tests, where ***, p < 0.001.
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Figure 8: Collagenolytic MMPs are induced by PAR2 activation and can antagonise further PAR2
activation. Data presented within this study demonstrate that canonical PAR2 activation is able to induce
MMP1 and MMP13 expression and subsequent secretion from chondrocytes, whilst the addition of MMP-1
to chondrocytes prior to canonical proteolytic stimulation results in an attenuated activation potential of
PAR2.
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